title: Pulmonary edema induced by angiotensin II in rats.
abstract: We performed this study to demonstrate the experimental procedure for inducing pulmonary edema by angiotensin II (AT II) in rats and to determine the mechanism of hemodynamic pulmonary edema. In the pilot study, 10 micrograms/ml of AT II was found to be adequate as the edematogenic dose for inducing pulmonary edema. The edematogenic dose of AT II was intravenously given to rats pretreated with 20 mg/kg of an AT II-receptor antagonist, E 4177 (3-[(2'-carboxybiphenyl-4-yl)methyl]-2-cyclopropyl-7-methyl-3H- imidazo[4,5-b]pyridine), and to rats given 10 mg/kg of an alpha-adrenergic blocker, phentolamine. Similarly, pulmonary edema was induced by 25 micrograms/ml of adrenaline in rats pretreated with E 4177 (20 mg/kg) and rats with no pretreatment. E 4177 completely suppressed the development of AT II-induced pulmonary edema, whereas phentolamine could not. On the contrary, E 4177 could not suppress the development of adrenaline-induced pulmonary edema. We concluded that AT II-induced pulmonary edema will develop via the specific AT II receptor without the indirect action of adrenaline.
authors.affiliation: Department of Preventive Medicine, Medical Research Institute, Tokyo Medical and Dental University, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Shimakura
authors.forename: M
authors.initials: M
authors.lastname: Sanaka
authors.forename: L
authors.initials: L
authors.lastname: Wang
authors.forename: S
authors.initials: S
authors.lastname: Mineshita
authors.forename: M
authors.initials: M
authors.lastname: Miyazaki
mesh_terms: D000804:Angiotensin II / Q000008:administration & dosage / Q000633:toxicity*; D057911:Angiotensin Receptor Antagonists; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004837:Epinephrine / Q000008:administration & dosage / Q000633:toxicity; D007093:Imidazoles / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D007275:Injections, Intravenous; D008297:Male; D005996:Nitroglycerin / Q000494:pharmacology / Q000627:therapeutic use; D010646:Phentolamine / Q000494:pharmacology / Q000627:therapeutic use; D010865:Pilot Projects; D011654:Pulmonary Edema / Q000139:chemically induced* / Q000503:physiopathology / Q000517:prevention & control; D011725:Pyridines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar
chemical_list: D057911:Angiotensin Receptor Antagonists; D007093:Imidazoles; D011725:Pyridines; D000804:Angiotensin II; C083778:3-((2'-carboxybiphenyl-4-yl)methyl)-2-cyclopropyl-7-methyl-3H-imidazo(4,5-b)pyridine; D005996:Nitroglycerin; D004837:Epinephrine; D010646:Phentolamine